Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2140)	1/31/2000 1:22:00 PM
From: pz	Respond to of 5582

Are you still short from 16 Hank? Ouch, that has to smart. Paul

To: Hank who wrote (2140)	1/31/2000 1:23:00 PM
From: DanZ	Read Replies (2) \| Respond to of 5582

Hank, Scientific proof is more important (or interesting) to some researchers, physicians, and scientists. It isn't important to most consumers. The value of Zicam will therefore be determined by consumers to a great extent and their vote so far is that it works and they are happy with the product. You say it didn't work for you. I say big deal; your experience is in the vast minority of people that I know and who have told the company otherwise. You say anecdotal evidence isn't good enough for you, but apparently it was good enough for you to establish a short position in GUMM. That is hypocritical and nuts (IMO) given the rapid increase in sales at this company. You also continue to ignore the gum business, and in particular, nicotine gum, which has the propensity to be even bigger than Zicam. Dental gum won't be insignificant either, IMO. Good luck with your short position. I believe that it will only get worse the longer you stay short. Dan

To: Hank who wrote (2140)	1/31/2000 8:59:00 PM
From: Carl R.	Read Replies (1) \| Respond to of 5582

Thank you for your response, Hank. If you tried the product, and it didn't work for you, I can understand why you would think that the short position is appropriate, since the company obviously is not financially strong and doesn't have a track record of consistent profits. <G> I rarely dabble in stocks like these that are heavily shorted, but I did take a long position because the product did work for me, and has worked for everyone that I know that has tried it. I do think that the results of the clinical trials will be important. I hope that this time the results get published, which will also many skeptics a better opportunity to evaluate the product. On the other hand successful clinical results may encourage others to offer a similar product next year. Good luck, Carl